Cytosorbents Corp 8-K Summary
Business Context and Reporting Period
Cytosorbents Corp (Nevada) filed this Current Report on Form 8-K on August 18, 2010, to disclose the entry into a material definitive agreement involving the issuance of debt securities to accredited investors.
Key Financial Metrics
- Debt Issuance: $800,000 in aggregate principal amount of Convertible Notes.
- Interest Rate: 8% per annum.
- Maturity Date: August 18, 2012.
- Repayment Method: Repayment in equity (Common Stock), not cash.
- Conversion Price: $0.10 per share.
- Warrant Coverage: 100% coverage with a tiered exercise price structure ($0.10, $0.125, and $0.15).
The filing does not provide specific values for revenue, profit, cash flow, margins, or existing liquidity positions.
Material Changes and Terms
The primary material change is the new debt obligation with significant equity conversion features:
- Conversion Rights: Investors may convert principal and accrued interest into Common Stock at $0.10 per share at any time during the term.
- Participation Rights: If the Company completes a subsequent financing of $750,000 or more, investors may exchange their notes into the new financing.
- Right of First Refusal: If an equity financing of less than $750,000 values the Company at or below $35 million (fully-diluted pre-money), investors have a right of first refusal to participate.
- Warrant Structure: Warrants are exercisable for five years with a cashless exercise provision. The coverage is split: 50% of principal at $0.10, 25% at $0.125, and 25% at $0.15.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the terms of the agreement. The securities were issued unregistered under Section 4(2) of the Securities Act and Rule 506 of Regulation D, relying on exemptions for private placements to accredited investors.
Investor Verification Checklist
- Verify the current cash position of the Company to assess the ability to service the 8% interest accrual until conversion or maturity.
- Confirm the fully-diluted share count to evaluate the immediate dilution impact if notes are converted at $0.10 per share.
- Review the Company's capitalization table to understand the potential dilution from the 100% warrant coverage.
- Monitor upcoming financing activities to determine if the $750,000 threshold for investor participation rights is triggered.
- Assess the likelihood of a financing event valuing the company at or below $35 million, which would trigger the right of first refusal.